Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial

2 Oct 2020

Abstract excerpt

The AKT inhibitor MK2206 (M) was evaluated in I-SPY 2 and graduated in the HER2+, HR-, and HR- HER2+ signatures. We hypothesized that AKT signaling axis proteins/genes may specifically predict response to M and tested 26 phospho-proteins and 10 genes involved in AKT-mTOR-HER signaling; in addition, we tested 9 genes from a previous study in the metastatic setting. One hundred and fifty patients had gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to PI3K/AKT/mTOR signaling in cancer
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33083527
DOI: 10.1038/s41523-020-00189-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trialPMID 33083527Read ↗

Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort.Semantic proximity Read ↗

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted TherapeuticsSemantic proximity Read ↗

Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.Semantic proximity Read ↗

Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyondSemantic proximity Read ↗

Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an AKT1 E17K-Mutated Tumor.Semantic proximity Read ↗

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trialsSemantic proximity Read ↗

Multi-omic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradationSemantic proximity Read ↗

A gene transcription signature of the Akt/mTOR pathway in clinical breast tumorsSemantic proximity Read ↗

Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT InhibitorsSemantic proximity Read ↗

Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIALSemantic proximity Read ↗

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.